Claire McCaskill actually said...
As Ranking Member McCaskill noted in a recent report entitled, "Fueling an Epidemic: Insys Therapeutics and the Systemic Manipulation of Prior Authorization," Insys revenues tripled and profits rose 45 percent between 2013 and 2015.
Context
McCaskill highlights Insys's financial growth amid opioid crisis concerns.
04/18/2018